These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35539172)

  • 1. The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an
    Zhang Q; Wang J; Zhang H; Liu D; Ming L; Liu L; Dong Y; Jian B; Cai D
    RSC Adv; 2018 Jul; 8(43):24084-24093. PubMed ID: 35539172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
    Cai D; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2014 Feb; 35(7):2283-94. PubMed ID: 24360410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer.
    Chen Y; Wang L; Luo S; Hu J; Huang X; Li PW; Zhang Y; Wu C; Tian BL
    Drug Des Devel Ther; 2020; 14():2945-2957. PubMed ID: 32801636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two methods for tumour-targeting peptide modification of liposomes.
    Huang SQ; Zhang HM; Zhang YC; Wang LY; Zhang ZR; Zhang L
    Acta Pharmacol Sin; 2023 Apr; 44(4):832-840. PubMed ID: 36271156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
    Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
    Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
    Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
    Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
    Zhang L; Wang Y; Yang Y; Liu Y; Ruan S; Zhang Q; Tai X; Chen J; Xia T; Qiu Y; Gao H; He Q
    ACS Appl Mater Interfaces; 2015 May; 7(18):9691-701. PubMed ID: 25845545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy.
    Qiu Y; Yu Q; Liu Y; Tang J; Wang X; Lu Z; Xu Z; He Q
    Pharm Res; 2018 Apr; 35(7):130. PubMed ID: 29700620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
    Chang Q; Geng R; Wang S; Qu D; Kong X
    Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy.
    Li L; Zhan Q; Yi K; Chen N; Li X; Yang S; Hou X; Zhao J; Yuan X; Kang C
    J Mater Chem B; 2022 Mar; 10(11):1833-1842. PubMed ID: 35212350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
    Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
    Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy.
    Zhao Y; Cai C; Liu M; Zhao Y; Pei W; Chu X; Zhang H; Wang Z; Han J
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110394. PubMed ID: 31398618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
    Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
    Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
    Gao B; Mu W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 39(8):769-74. PubMed ID: 25202944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Antitumor Activity of Novel Redox-Responsive Paclitaxel-Encapsulated Liposomes Based on Disulfide Phosphatidylcholine.
    Du Y; Wang Z; Wang T; He W; Zhou W; Li M; Yao C; Li X
    Mol Pharm; 2020 Jan; 17(1):262-273. PubMed ID: 31747284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.
    Xia T; He Q; Shi K; Wang Y; Yu Q; Zhang L; Zhang Q; Gao H; Ma L; Liu J
    Pharm Dev Technol; 2018 Jan; 23(1):13-21. PubMed ID: 27884084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
    Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
    Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.